Though intravitreal route appears to be a promising route to attain high drug concentrations in back of the eye (retina/choroid), however, this route is often limited by post dosing adverse effects, such as development of endophthalmitis, blurred vision, increase in intraocular pressure, cataract formation and increased risk of retinal detachment. Current momentum in the development of new drug delivery systems hold promise for improved therapies in the treatment of vision threatening vascular degenerative disorders of the posterior eye, such as age-related macular degeneration (AMD), diabetic macular edema (DME) and proliferative vitreoretinopathy (PVR). New technologies that can provide controlled, scalable and sustained release of therapeutic proteins (biologics), through non-invasive or minimally invasive routes for targeting intraocular tissues, are warranted.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society.
Last date updated on February, 2021